Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Photocure ASA ( (PHCUF) ) is now available.
Photocure ASA has partnered with Intelligent Scopes Corporation to develop AI software integrated with blue light cystoscopy for improved bladder cancer detection. This collaboration aims to enhance early-stage detection and diagnosis, potentially transforming bladder cancer management and improving patient care by leveraging AI technology for more precise diagnostics.
More about Photocure ASA
Photocure ASA, known as The Bladder Cancer Company, is a leader in bladder cancer diagnostics, offering transformative solutions to improve patient outcomes. Its flagship products, Hexvix®/Cysview®, enhance bladder cancer detection through blue light cystoscopy. The company is headquartered in Oslo, Norway, and is publicly traded on the Oslo Stock Exchange.
Average Trading Volume: 52,514
Current Market Cap: NOK1.47B
Find detailed analytics on PHCUF stock on TipRanks’ Stock Analysis page.